Press Release – Page 5 – Kalytera Therapeutics, Inc.

Kalytera Will Not Proceed with Vote on Potential Share Consolidation

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that after consultations with major shareholders, the board of directors of the Company has decided not to proceed at this time with the shareholder vote...

Kalytera In GVHD, Press Release

Kalytera Announces Completion of Food Effect and QTc Study

Study is Part of Program Evaluating CBD for Prevention of GVHD Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has completed Study KAL-07, the Food Effect and QTc Study, that is...

Kalytera In Press Release

Kalytera to Hold Annual and Special Meeting on July 29, 2019

Will Seek Advance Approval for Potential Share Consolidation Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it is holding its annual and special meeting of shareholders on July 29, 2019 (together with...

Kalytera In Press Release

Kalytera to Acquire CBD Extraction Business

Business Will Be Amongst Largest Such Operations in U.S. Transaction Will Provide Near-Term Path to Revenues Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has signed a Letter of Intent (“LOI”)...

Kalytera In GVHD, Press Release

Kalytera Provides Update on GVHD Program

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Phase 2 Clinical Study...

Kalytera In Press Release

Kalytera Announces Grant of Stock Options to Directors

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on June 19, 2019 to the directors of the Company. The stock options have an exercise price of $0.05...

Kalytera In Press Release

Kalytera Announces Changes to Board of Directors

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced changes to the Company’s Board of Directors (the "Board"). Mr. Robin “Rob” Hutchison has joined the Board to fill the vacancy created by the resignation...

Kalytera In Pain, Press Release

Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor. Activation...

Kalytera In Press Release

Kalytera Reports First Quarter 2019 Financial Results

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the first quarter of 2019. (All dollars U.S. unless otherwise noted.) “Since the beginning of the year, we have made important progress...

Kalytera In GVHD, Press Release

Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

Claims Cover Treatment of Ulcerative Colitis, Crohn’s Disease, Inflammatory Bowel Disease, GVHD and other Inflammatory Diseases of the GI Tract Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a...